1. Home
  2. BEAT vs FEMY Comparison

BEAT vs FEMY Comparison

Compare BEAT & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Heartbeam Inc.

BEAT

Heartbeam Inc.

N/A

Current Price

$0.50

Market Cap

27.7M

Sector

Technology

ML Signal

N/A

Logo Femasys Inc.

FEMY

Femasys Inc.

N/A

Current Price

$5.81

Market Cap

24.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BEAT
FEMY
Founded
2015
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.7M
24.8M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
BEAT
FEMY
Price
$0.50
$5.81
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$5.63
$5.50
AVG Volume (30 Days)
397.6K
1.6M
Earning Date
05-08-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
15.07
44.71
EPS
N/A
N/A
Revenue
N/A
$2,293,313.00
Revenue This Year
N/A
$105.16
Revenue Next Year
$315.97
$200.23
P/E Ratio
N/A
N/A
Revenue Growth
N/A
40.77
52 Week Low
$0.47
$0.29
52 Week High
$4.00
$6.29

Technical Indicators

Market Signals
Indicator
BEAT
FEMY
Relative Strength Index (RSI) 39.50 N/A
Support Level N/A N/A
Resistance Level $0.63 N/A
Average True Range (ATR) 0.03 0.00
MACD 0.00 0.00
Stochastic Oscillator 7.78 0.00

Price Performance

Historical Comparison
BEAT
FEMY

About BEAT Heartbeam Inc.

HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Share on Social Networks: